The Foundation announced than an international scientific congress on therapeutic research concerning genetic intellectual disability is going to be held.
(Pasteur Institute – 24th to 26th March 2011)
For the publication of promising results during a clinical trial on patients with Fragile-X Syndrome in the Translational Science Medicine magazine, the Jérôme Leujeune Foundation has announced an international scientific congress on genetic intellectual disability and its therapeutic progress, from the 24th to the 25th of March this year at the Pasteur Institute:
Genetic Intellectual disability:
Progressing towards targeted treatments?
The congress will bring together international scientifics and researchers specialised in treatment research for genetic intellectual diseases*.
The president of the congress is Pr. Randi Hagerman, medical director of the M.I.N.D. Institute UC Davis Health System in Sacramento (California) and world expert in therapeutic research for Fragile-X.
Among the speakers specialized in Down Syndrome there will be:
Pr. William Mobley, professor in neuropediatrics at the university in San Diego and author of a publication which drew attention in November 2009.
Pr. Stylianos Antonarakis, head of the genetics unit department in Geneva and leader of the therapeutic European project AnEUploidy
Pr. Jean Delabar, researcher at the University in Paris Diderot, whose work was published in March 2009 and enabled to start a phase I clinical trial involving the EGCG molecule (epigallocatechine gallate). This trial was led by Pr. Mara Diersson from the Genomics Regulation Centre in Barcelona, who will also intervene during the congress.
Pr. Vincent Desportes (member of the Jérôme Lejeune scientific council) and Pr. Sébastien Jacquemont, who have been doing the current clinical trial for Fragile-X, will also be speakers during the congress.
Their original and encouraging work confronts the legitimacy of research programmes which are led in order to find treatments which would restore the intellectual capacities of people living with genetic intellectual diseases, such as Down Syndrome.
After the first International Jérôme Lejeune Days, in 2004 (theme: genetic intellectual diseases, from molecular biology to treatment) and the first Clinical Jérôme Lejeune Days, in 2006 (theme: genetic intellectual diseases: care and therapeutic perspectives), this 2011 congress will be an opportunity for the greatest international researchers doing fundamental research and clinicians to present their latest scientific discoveries.
The scientific interventions will take place from Thursday, 24th March to Saturday, 26th March at lunchtime and will be followed by a meeting in the afternoon for families and associations with the participation of Ms Christel Prado, president of UNAPEI.
All practical information and scientific programme on www.jijl.net
*Genetic intellectual diseases include pathologies whose origin is genetic and which are manifested, among other things, by intellectual disability involving a loss of autonomy. The most frequent one is Down Syndrome (1 conception out of 700). There are also Fragile-X Syndrome, Rett Syndrome, Cri Du Chat Syndrome, Prader-Willi or Angelman Syndrome, Smith-Magenis Syndrome, Williams-Beuren Syndrome and many other rare diseases.
Recognized of public utility since 1996, the Jérôme Lejeune Foundation is the 1st financer for research in France for genetic intellectual diseases (in 2003, 3 million euros for Down Syndrome) and the first centre for medical consultations specialized in these pathologies in France (5000 patients).